Enovis targets robotic surgery expansion with €155M eCential Robotics deal. September 1, 2026 Key points. * Enovis has made a binding offer to acquire eCential Robotics for an enterprise value of €155 million, with up to €35 million in milestone payments. The deal is expected to close by the end of 2026 and will be funded with cash and revolving-credit capacity. * The acquisition expands Enovis' ASTRA ecosystem into robotics, with plans to launch a next-generation platform for total knee procedures within two years and pursue a shoulder application afterward. Initial commercial contributions are expected in 2028. * Enovis expects the deal to temporarily dilute adjusted EBITDA margins by roughly 100 basis points in 2027 after underlying improvements, while leverage rises by about half a turn. The company still targets at least $100 million in free cash flow next year and expects margin benefits as robotics sales develop. * MarketBeat previews the top five stocks to own by October 1st. Enovis NYSE: ENOV said it has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics technology, in a move the orthopedic company said will expand its enabling-technology capabilities and accelerate its pathway into robotic surgery. Chief Executive Officer Damien McDonald said the proposed acquisition is intended to supplement Enovis' existing ASTRA ecosystem of planning and navigation technologies. The company aims to offer surgeons a connected platform spanning planning, navigation and robotic capabilities across hospitals, outpatient clinics and ambulatory surgery centers. "The eCential transaction is more than just a robot," McDonald said. "It is a deliberate strategy to reinforce Enovis' growth trajectory with a credible long-term position in robotics and advanced enabling tech." Transaction terms and timeline. Chief Financial Officer Ben Berry said the initial upfront consideration is based on an enterprise value of €155 million, representing about €176 million in cash to be paid to eCential shareholders at closing. The agreement also includes up to €35 million in contingent payments tied to development milestones for knee and shoulder product introductions. Enovis expects the deal to close by the end of 2026, subject to customary regulatory approvals. The company plans to finance the acquisition through cash on hand and available capacity under its revolving credit facility. Berry said the transaction would initially add about one-half turn to leverage. Enovis reduced leverage to 3.1 times from 3.8 times over the preceding 12 months and expects to return to roughly 3 times leverage by the end of 2027. Robotics development plans. Enovis said it plans to bring a next-generation robotic platform to market within two years, starting with total knee procedures. The company expects an initial commercial contribution beginning in 2028, according to its remarks. A shoulder application is expected to follow. McDonald said eCential brings more than 50 employees with experience designing, developing and supporting the launch of three robotic platforms across orthopedics and spine. Group President of Reconstructive Louie Vogt said the Grenoble-based team is primarily focused on software and hardware engineering, with quality, regulatory, manufacturing and assembly capabilities. He said its current assembly output is estimated at 75 to 100 robots annually. For knee surgery, Enovis said it will develop planning capabilities that use CT imaging to create a virtual surgical application and the software foundation that will drive the robot. Vogt said the company also intends to incorporate surgeon and key opinion leader input into the product-development process. In shoulder procedures, Enovis sees an opportunity to develop a more differentiated offering. McDonald said the company has significant global market share in total shoulder arthroplasty and believes a robotic arm with seven degrees of freedom could differentiate its platform. Vogt said Enovis already has shoulder planning and navigation capabilities, while robotic shoulder surgery remains a relatively early market. eCential's proprietary robotic control layer is expected to integrate with Enovis' AI-enabled planning and navigation technology, the company said. Vogt said Enovis intends to use a unified portal, navigation core, camera tracking, software code base, workflow and user interface across ASTRA ARVIS and the future robotics platform. Commercial strategy and spine operations. Vogt said Enovis expects to use a hybrid commercial model, augmenting its distributor channel with corporate resources ranging from enterprise-solutions personnel to clinical success managers. The company has begun building related capabilities through the rollout of its ARVIS ecosystem. For ambulatory surgery centers, Vogt said Enovis expects to tailor its offering based on an account's procedure volume and economic needs. He said company research suggests that facilities performing fewer than 100 knee procedures annually may not be well suited to a large-format robot, though he noted that this would not apply in every case. ARVIS is expected to remain part of the company's approach for accounts with different requirements. eCential currently has a spine solution and has developed Johnson & Johnson's Velys spine robot, McDonald said. However, Enovis said it does not intend to enter the surgical spine market. It plans to support eCential's existing spine agreements and relationships while focusing its own development efforts on knee and shoulder applications. Margin and cash flow expectations. Berry said Enovis expects the acquisition to create approximately 150 basis points of adjusted EBITDA margin dilution in 2027, partly offset by about 50 basis points of underlying improvement, for a net headwind of roughly 100 basis points. The company attributed most of the dilution to the operating expenses and infrastructure acquired with eCential, along with additional investment to accelerate product development. Enovis expects 50 basis points of year-over-year underlying margin improvement in 2028. It said initial commercial traction should begin offsetting operating costs in mid-2028, with 100 basis points of margin improvement anticipated in 2029. Despite the planned investment, Enovis reaffirmed its expectation for free-cash-flow conversion of about 50% in 2027 and committed to generating at least $100 million in absolute free cash flow next year. The company expects free-cash-flow conversion to rise to approximately 70% in 2029. About Enovis (NYSE:ENOV). Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation. The company's flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Enovis, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list. While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Enovis reaffirms guidance after solid first half. Enovis reported 2Q26 orthopedic sales of $294.5 million, up 7.5% compared to the second quarter of 2025. For the first half, the company generated $611.7 million in orthopedic sales, up 9.2% compared to the prior period. Newer product introductions helped drive strong sales results in the quarter. Enovis' Nebula hip saw 80% of its new instrument set deployments going to competitive users. Additionally, ARVIS reached full commercial launch in the U.S. during the quarter, and the company expects accelerating adoption among shoulder surgeons in the second half of 2025. Enovis said that while there's a lot of noise in the market, it sees the U.S. orthopedic market as stable with no change in underlying dynamics. However, Western Europe volumes have slipped mainly on transient factors like strikes, wildfires and heatwaves. The company reaffirmed its 2026 guidance of total sales between $2.31 billion and $2.37 billion. It expects seasonal softness in the third quarter, followed by accelerating volumes in the fourth quarter. Orthopedic sales data. Unless otherwise noted, all orthopedic sales data is provided in USD millions. Orthoworld estimate orthopedic sales and growth rates on an as-reported basis. Orthopedic sales by Segment. | Segment | 2Q26 | 2Q25 | $ Chg | % Chg | | Joint Replacement | $252.7 | $235.6 | $17.1 | 7.3% | | Knees | $63.3 | $60.3 | $3.1 | 5.1% | | Hips | $83.9 | $80.0 | $3.9 | 4.9% | | Extremities | $105.4 | $95.3 | $10.1 | 10.6% | | Trauma | $30.3 | $27.9 | $2.4 | 8.6% | | Other | $11.5 | $10.4 | $1.1 | 10.3% | | Total | $294.5 | $274.0 | $20.6 | 7.5% | | Segment | 1H26 | 1H25 | $ Chg | % Chg | | Joint Replacement | $528.0 | $482.9 | $45.0 | 9.3% | | Knees | $127.4 | $119.0 | $8.4 | 7.1% | | Hips | $174.3 | $163.0 | $11.3 | 6.9% | | Extremities | $226.3 | $201.0 | $25.3 | 12.6% | | Trauma | $60.5 | $55.7 | $4.8 | 8.5% | | Other | $23.2 | $21.6 | $1.6 | 7.6% | | Total | $611.7 | $560.2 | $51.4 | 9.2% | Orthopedic sales by geography. | Region | 2Q26 | 2Q25 | $ Chg | % Chg | | US | $137.8 | $129.5 | $8.3 | 6.4% | | OUS | $156.7 | $144.5 | $12.2 | 8.5% | | EMEA | $115.2 | $108.4 | $6.8 | 6.3% | | APAC | $23.8 | $20.9 | $2.9 | 13.7% | | ROW | $17.7 | $15.2 | $2.5 | 16.7% | | Total | $294.5 | $274.0 | $20.6 | 7.5% | | Region | 1H26 | 1H25 | $ Chg | % Chg | | US | $287.0 | $267.4 | $19.7 | 7.4% | | OUS | $324.6 | $292.9 | $31.8 | 10.9% | | EMEA | $242.0 | $221.1 | $20.8 | 9.4% | | APAC | $47.5 | $41.7 | $5.8 | 13.8% | | ROW | $35.2 | $30.0 | $5.2 | 17.2% | | Total | $611.7 | $560.2 | $51.4 | 9.2% | Company Earnings. | / | Amt | % of Sales | | Sales | $17.2 | / | | Cost of Sales | $3.7 | 21.7% | | Sales and Marketing | $20.1 | 116.9% | | R & D | $3.4 | 19.7% | | Other | $0.1 | 0.7% | | Net Earnings | ($10.2) | (59.1%) | Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Enovis Corp reported 5% organic growth in Q2 2026, with US reconstruction growing 6% and hips/knees up 8%. The medical device company's innovation portfolio showed strong momentum, with its Avis robotic system now in full commercial launch and over 80% of new instrumentation sets going to competitive users. Adjusted gross margins improved by 120 basis points, driven by productivity and mix improvements despite tariff and inflationary pressures. Free cash flow turned positive in the first half, improving by $27 million year-over-year, whilst leverage decreased to 3.1x. However, the company's Prevention and Recovery (PNR) segment grew only 3% organically, with international markets affected by Middle East conflict creating a 100 basis point headwind. Enovis faces $10 million in full-year inflationary pressure from raw materials and freight. Management reaffirmed 2026 guidance and expressed confidence in accelerating Q4 growth, supported by new product launches.